NEW YORK (TheStreet) -- Endocyte  (ECYT) - Get Report plummeted more than 60% to a one-year low of $6.50 on Friday after the biopharmaceutical company stopped a late-stage trial of its experimental ovarian cancer drug.

The trial tested Vynfinit (vintafolide) in combination with a chemotherapy drug called pegylated liposomal doxorubicin (PLD) against a combination of PLD and a placebo. The drug did not improve survival rates in subjects without the cancer worsening.

Independent monitors had been reviewing the trial and recommended halting the trial.

Must Read: Endocyte Falls on Ovarian Cancer Drug Blowup

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Robert W. Baird downgraded the stock to "neutral" in the wake of the news.

The stock was down 62.26% to $6.56 at 11:07 a.m. More than 11 million shares had changed hands, which easily beat the average volume of 1,363,470.

For more on this story, read TheStreet's Adam Feuerstein's article here.

Image placeholder title

ECYT data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.